The two initiatives include supporting the global introduction of our InSpectra StO2 Spot Check, which received marketing clearance from the US Food and Drug Administration in March. This new product enables clinicians to quickly and cost effectively experience the clinical and economic benefits of using StO2 to identify at-risk patients in a wide variety of clinical settings, and we believe could lead to wider adoption of StO2 monitoring.
In addition, an independent randomized multi-site outcomes based study is being conducted to research the possible benefits of using StO2 to guide resuscitation of shock patients. And initial studies show that using StO2 to guide patient treatment resulted in improved outcomes in the form of shorter ICU and hospital stays. If the multi-site outcome study demonstrates these results in a larger patient population, it could add significantly to the growing body of evidence that supports wider adoption of StO2 monitoring. All together, our consolidation and restructuring effort should result in a $50 million to $55 million reduction in our costs on an annualized basis by the start of fiscal 2012 second quarter.
We believe we have the right plans in place to provide compelling combination of cost, technology, service, and supply assurance to our customers, and profitable growth to our shareholders.
I’ll turn it over to Rick now for a recap of the Disk Drive Component Division second quarter.Rick Penn Thanks Wayne. During our fiscal 2011 second quarter, we shipped 102.3 million suspension assemblies, down 4% from a 106.5 million in the preceding quarter. This decline was in line with our revised guidance as well as the estimated reduction in the overall hard disk drive and suspension assembly TAM or total available market. Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV